ZYME: רווח נקי למניה (EPS TTM) Zymeworks Corp

Geopolitical fragmentation and sanctions are complicating the global trials of Zymeworks Inc. (ZYME), which dominates the market trend. The rolling net income per share trend captures these complexities, with the latest value recorded as 0.52. Stability is supported by the implementation of AI molecule screening and the aggressive retention of leading immunologists through option programs to combat talent shortages.

For Zymeworks Inc. (ZYME), which monetizes its multispecific antibody platform through licensing agreements, the net income per share trend reflects the efficiency of converting R&D assets into real capital. The EPS TTM metric aggregates net income over the year and divides it by the number of shares, allowing investors to assess the actual return on ownership and determine the extent of any overpayment for the asset.